Healios K.K. (HLOSF)

Market Cap	283.83M +111.7%
Revenue (ttm)	655.45K -82.3%
Net Income	-26.29M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	1,737
Open	2.100
Previous Close	1.930
Day's Range	2.100 - 2.100
52-Week Range	1.900 - 4.450
Beta	1.52
RSI	42.97
Earnings Date	Feb 16, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLOSF

Financial Performance

In 2024, Healios K.K.'s revenue was 560.00 million, an increase of 362.81% compared to the previous year's 121.00 million. Losses were -4.24 billion, 10.8% more than in 2023.

Financial numbers in JPY